MX2009010173A - Derivados de aminometil aza-adamantano y uso de los mismos como moduladores selectivos del receptor de acetilcolina nicotinico alfa-7 neuronal (nnrs). - Google Patents

Derivados de aminometil aza-adamantano y uso de los mismos como moduladores selectivos del receptor de acetilcolina nicotinico alfa-7 neuronal (nnrs).

Info

Publication number
MX2009010173A
MX2009010173A MX2009010173A MX2009010173A MX2009010173A MX 2009010173 A MX2009010173 A MX 2009010173A MX 2009010173 A MX2009010173 A MX 2009010173A MX 2009010173 A MX2009010173 A MX 2009010173A MX 2009010173 A MX2009010173 A MX 2009010173A
Authority
MX
Mexico
Prior art keywords
acetylcholine receptor
nicotinic acetylcholine
amimomethyl
nnrs
alpha7
Prior art date
Application number
MX2009010173A
Other languages
English (en)
Inventor
William H Bunnelle
Lei Shi
Marc J C Scanio
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2009010173A publication Critical patent/MX2009010173A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos que son derivados de aminometil aza-adamantano substituidos de la fórmula (I), composiciones que comprenden dichos compuestos, y el uso de dichos compuestos y composiciones para tratar o prevenir condiciones, trastornos o déficits modulados por un receptor de acetilcolina nicotínico a7, receptor de acetilcolina nicotínico a4ß2, o tanto el receptor de acetilcolina nicotínico a7 como a4ß2, en donde la condición, trastorno o déficit se selecciona del grupo que consiste de un trastorno de la memoria, trastorno cognitivo, neurodegeneración, y trastorno de neurodesarrollo.
MX2009010173A 2007-03-23 2008-03-20 Derivados de aminometil aza-adamantano y uso de los mismos como moduladores selectivos del receptor de acetilcolina nicotinico alfa-7 neuronal (nnrs). MX2009010173A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89675507P 2007-03-23 2007-03-23
PCT/US2008/057652 WO2008118747A1 (en) 2007-03-23 2008-03-20 Amimomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (nnrs)

Publications (1)

Publication Number Publication Date
MX2009010173A true MX2009010173A (es) 2009-10-12

Family

ID=39620402

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010173A MX2009010173A (es) 2007-03-23 2008-03-20 Derivados de aminometil aza-adamantano y uso de los mismos como moduladores selectivos del receptor de acetilcolina nicotinico alfa-7 neuronal (nnrs).

Country Status (7)

Country Link
US (1) US8168791B2 (es)
EP (2) EP2129673B1 (es)
JP (1) JP5394940B2 (es)
CN (1) CN101675049A (es)
CA (1) CA2679885A1 (es)
MX (1) MX2009010173A (es)
WO (1) WO2008118747A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2443122B1 (en) * 2009-06-19 2014-03-05 AbbVie Inc. Diazahomoadamantane derivatives and methods of use thereof
JP6612874B2 (ja) 2014-12-16 2019-11-27 アクソファント サイエンシーズ ゲーエムベーハー α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換キヌクリジンアミド化合物
RU2017145964A (ru) 2015-06-10 2019-07-10 Аксовант Сайенсиз Гмбх Аминобензизоксазольные соединения в качестве агонистов α7-никотиновых ацетилхолиновых рецепторов
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8523211D0 (en) 1985-09-19 1985-10-23 Beecham Group Plc Compounds
US5260303A (en) 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5280028A (en) 1992-06-24 1994-01-18 G. D. Searle & Co. Benzimidazole compounds
US5434151A (en) 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5840903A (en) * 1992-07-27 1998-11-24 G. D. Searle & Co. 4-aminomethyl-1-azaadamantane derived benzamides
JP3235913B2 (ja) * 1993-07-30 2001-12-04 エーザイ株式会社 アミノ安息香酸誘導体
US5399562A (en) 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
US7897766B2 (en) * 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use

Also Published As

Publication number Publication date
EP2505588B1 (en) 2013-11-13
WO2008118747A1 (en) 2008-10-02
US8168791B2 (en) 2012-05-01
EP2129673B1 (en) 2013-11-06
CA2679885A1 (en) 2008-10-02
CN101675049A (zh) 2010-03-17
US20080262023A1 (en) 2008-10-23
JP2010522204A (ja) 2010-07-01
EP2129673A1 (en) 2009-12-09
JP5394940B2 (ja) 2014-01-22
EP2505588A1 (en) 2012-10-03

Similar Documents

Publication Publication Date Title
MY189750A (en) Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
MX2010005648A (es) Derivados de alcano azabiciclico sustituidos con biarilo como moduladores de la actividad del receptor nicotinico de acetilcolina.
WO2010045258A3 (en) Spirocyclic gpr40 modulators
WO2007140439A3 (en) Compounds as cannabinoid receptor ligands and uses thereof
WO2009059994A3 (en) Methods and compositions for measuring wnt activation and for treating wnt-related cancers
WO2008152099A3 (en) Aryl/hetarylamides as modulators of the ep2 receptor
WO2009016253A3 (en) Cyanomethyl substituted n-acyl tryptamines
WO2007053765A3 (en) Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
MX2012005559A (es) Moduladores heterociclicos selectivos del receptor de esfingosina 1 fosfato.
EA200900831A1 (ru) Модуляторы никотиновых ацетилхолиновых рецепторов
GB0510143D0 (en) Novel compounds A1
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2006123249A3 (en) Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
MY160907A (en) Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
WO2012158550A3 (en) Selective heterocyclic sphingosine 1 phosphate receptor modulators
MX2009010173A (es) Derivados de aminometil aza-adamantano y uso de los mismos como moduladores selectivos del receptor de acetilcolina nicotinico alfa-7 neuronal (nnrs).
WO2007042544A3 (en) Imidazole derivatives and their use for modulating the gabaa receptor complex
WO2010057088A3 (en) Pyrrolidinyl modulators of nicotinic acetylcholine receptors
WO2009037542A3 (en) Spirocyclic compounds as stearoyl coa desaturase inhibitors
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights